DA-302168S

Phase 2Small molecule

CChendu DIAO Pharmaceutical Group CO., LTD.

DA-302168S is one of 85 small molecule programs targeting Type 2 Diabetes Mellitus. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Type 2 Diabetes MellitusNot yet recruiting

OverweightActive, not recruiting

Type 2 Diabetes MellitusPhase 2

Not yet recruiting

OverweightPhase 2

Active, not recruiting

Competition

Competitive Landscape

150 competitors in Type 2 Diabetes Mellitus

#DrugCompanyPhaseTrials

GZR18

GGan & Lee Pharmaceuticals.

Phase 3

5 2

HDM1002

HHangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.

Phase 3

3 3

Elecoglipron

AstraZeneca

Phase 3

5 4

GZR4

GGan and Lee Pharmaceuticals, USA

Phase 3

5 5

Ganagliflozin

HHangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.

Phase 3

1 6

HM11260C

Hanmi Pharmaceutical Company Limited

Phase 3

3 7

TG103

CCSPC Baike (Shandong) Biopharmaceutical Co., Ltd.

Phase 3

2 8

NOVOLIN R

Novo Nordisk

Preclinical

1 9

Adenocard

Astellas

Preclinical

1 10

Dostinex

Pfizer

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 3Recruiting

Overweight and Obesity

NCT07629544

Phase 2Not yet recruiting

Type 2 Diabetes Mellitus

NCT07755150

Clinical

Trials by Indication[1]

Overweight2 trials

A Study to Evaluate the Efficacy and Safety of DA-302168S Tablets in Overweight/Obese Subjects

Active, not recruiting·CChendu DIAO Pharmaceutical Group CO., LTD.·Phase 2·NCT06953063·240 enrolled

A Study Evulating DA-302168S Tablets in Overweight/Obese Subjects

Completed·CChendu DIAO Pharmaceutical Group CO., LTD.·Phase 1·NCT06541730·48 enrolled

Tics2 trials

The Food Effect on Pharmacokinetics of DA-302168S

Completed·CChendu DIAO Pharmaceutical Group CO., LTD.·Phase 1·NCT06534346·16 enrolled

Safety, Tolerability and Pharmacokinetic Characteristics Evaluation of DA-302168S Tablets

Completed·CChendu DIAO Pharmaceutical Group CO., LTD.·Phase 1·NCT06534320·50 enrolled

Type 2 Diabetes Mellitus1 trial

A Multicenter, Randomized, Double-blind, Parallel, Placebo-controlled Phase II Study Assessing the Efficacy and Safety of DA-302168S Tablets in Subjects With Type 2 Diabetes Mellitus.

Not yet recruiting·CChendu DIAO Pharmaceutical Group CO., LTD.·Phase 2·NCT07755150·272 enrolled

Overweight and Obesity1 trial

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of DA-302168S Tablets in Overweight/Obese Participants

Recruiting·CChendu DIAO Pharmaceutical Group CO., LTD.·Phase 3·NCT07629544·840 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for DA-302168S. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — DA-302168S compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for DA-302168S. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Chendu DIAO Pharmaceutical Group CO., LTD. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: CChendu DIAO Pharmaceutical Group CO., LTD.

DA-302168S

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Overweight2 trials

Tics2 trials

Type 2 Diabetes Mellitus1 trial

Overweight and Obesity1 trial

References

Drug Info

Quick Facts

Related News